利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.033 秒)

    T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2
    12.
    发明授权
    T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2 有权

    公开(公告)号：US10040865B2

    公开(公告)日：2018-08-07

    申请号：US15364953

    申请日：2016-11-30

    申请人： MEMORIAL SLOAN KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

    发明人： David Scheinberg ,  Tao Dao ,  Cheng Liu ,  Su Yan

    IPC分类号： A61K39/00 ,  C07K16/32 ,  C07K16/28 ,  G01N33/574 ,  C07K16/18 ,  A61K47/68

    摘要： The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.

    T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2
    13.
    发明申请
    T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2 有权
    T细胞受体 - HLA-A2提供的WTI肽特异性抗体

    公开(公告)号：US20150259436A1

    公开(公告)日：2015-09-17

    申请号：US14724155

    申请日：2015-05-28

    申请人： Memorial Sloan Kettering Cancer Center ,  Eureka Therapeutics, Inc.

    发明人： David Scheinberg ,  Tao Dao ,  Cheng Liu ,  Su Yan

    IPC分类号： C07K16/32 ,  A61K47/48

    CPC分类号： C07K16/32 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/2833 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/732 ,  G01N33/5748

    摘要： The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.

    摘要翻译： 本发明提供特异性结合Wilms肿瘤蛋白（WT1）的抗原结合蛋白，包括针对WT1的人源化，嵌合和完全人抗体，抗体片段，嵌合抗原受体（CAR），融合蛋白及其缀合物。 抗原结合蛋白和抗体结合HLA-A0201限制性WT1肽。 此类抗体，片段，融合蛋白及其结合物可用于治疗WT1相关癌症，包括例如乳腺癌，卵巢癌，前列腺癌，慢性骨髓性白血病，多发性骨髓瘤，急性淋巴细胞性白血病（ALL），急性骨髓/ 骨髓性白血病（AML）和骨髓增生异常综合征（MDS）。 在更具体的实施方案中，抗WT1 / A抗体可以包含设计用于改善蛋白质稳定性，抗体结合和/或表达水平的一个或多个框架区氨基酸取代。